Daily Mobility Leads to Better ICU Outcomes
By Lori Solomon HealthDay Reporter
FRIDAY, May 10, 2024 -- More out-of-bed mobility interventions for critically ill patients are associated with better intensive care unit (ICU) outcomes, according to a study published online May 1 in the American Journal of Critical Care.
Sarina A. Fazio, Ph.D., R.N., from UC Davis Health in Sacramento, California, and colleagues examined associations between daily doses of out-of-bed mobility and patient outcomes in ICUs. The analysis included electronic record data from seven adult ICUs in an academic quarternary hospital (8,609 adults from 2015 through 2018).
The researchers found that patients were mobilized out of bed on 46.5 percent of ICU days and were eligible for mobility interventions on a median of 2.0 of 2.7 ICU days. For all patients, median out-of-bed events per mobility-eligible day were 0.5. Mechanical ventilation duration decreased by 10 percent for every unit increase in out-of-bed events per mobility-eligible day before extubation. Additionally, daily mobility increased ICU stays by 4 percent but decreased hospital stays by 5 percent. There were differences in effect sizes among ICUs.
"Our findings support a dose-response relationship between mobility and specific patient outcomes," Fazio said in a statement. "Associations differed across ICU patient populations, raising important questions as to how frequently, how intensively, and for how long therapy should be provided for people in different units."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.